within Pharmacolibrary.Drugs.ATC.J;

model J02AX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.009166666666666667,
    adminDuration  = 600,
    adminMass      = 0.07,
    adminCount     = 1,
    Vd             = 0.009699999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Caspofungin is an echinocandin antifungal agent approved for the treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies, as well as for empirical therapy for presumed fungal infections in febrile neutropenic patients. It is also used against Candida infections, including candidemia and esophageal candidiasis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers and patients with invasive fungal infections. Intravenous infusion. Parameters represent typical administration of a 70 mg loading dose followed by 50 mg daily.</p><h4>References</h4><ol><li><p>Borsuk-De Moor, A, et al., &amp; Wiczling, P (2020). Nonstationary Pharmacokinetics of Caspofungin in ICU Patients. <i>Antimicrobial agents and chemotherapy</i> 64(9) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00345-20&quot;>10.1128/AAC.00345-20</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32601169/&quot;>https://pubmed.ncbi.nlm.nih.gov/32601169</a></p></li><li><p>Leshinsky, J, et al., &amp; Barrs, VR (2017). Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. <i>PloS one</i> 12(6) e0178783–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0178783&quot;>10.1371/journal.pone.0178783</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28575121/&quot;>https://pubmed.ncbi.nlm.nih.gov/28575121</a></p></li><li><p>Yu, IG, et al., &amp; Ryckman, DM (2021). Pharmacokinetic and Pharmacodynamic Comparison of Intravenous and Inhaled Caspofungin. <i>Journal of aerosol medicine and pulmonary drug delivery</i> 34(3) 197–203. DOI:<a href=&quot;https://doi.org/10.1089/jamp.2020.1645&quot;>10.1089/jamp.2020.1645</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32985935/&quot;>https://pubmed.ncbi.nlm.nih.gov/32985935</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J02AX04;
